1. Health
Send to a Friend via Email

Discuss in my forum

Carol Eustice

Xeljanz - What Arthritis Patients Should Know

By November 21, 2012

Follow me on:

On November 6, 2012, the FDA approved Xeljanz (tofacitinib). We blogged about the approval of Xeljanz, a JAK inhibitor intended for the treatment of adults with moderate to severe rheumatoid arthritis who've had an inadequate response to methotrexate.

I've put together more information about Xeljanz. Find out how the drug works, how it performed in clinical trials, as well as information about common side effects, warnings, and cost in Xeljanz - What You Need to Know.

Related Articles:

Follow Me:

Facebook | Twitter | Message Board | Newsletter

Photo by dimshik (stock.xchng)

Comments
No comments yet. Leave a Comment
Leave a Comment

Line and paragraph breaks are automatic. Some HTML allowed: <a href="" title="">, <b>, <i>, <strike>
Top Related Searches
  • arthritis patients
  • arthritis
  • ©2014 About.com. All rights reserved.

    We comply with the HONcode standard
    for trustworthy health
    information: verify here.